Development of new interventions against human disease requires complex in vivo analysis in preclinical animal models. Preclinical animal models have been unable to accurately predict the effects of novel therapeutics on human diseases due to significant biological differences between most animal models and humans.
HuMurine Technologies was founded in 2008 by Gerold Feuer, Ph.D., to standardize and generate a reproducible humanized mouse model, which is acceptable and accessible to both commercial and academic clients. Humanized mice are generated by injection of human hematopoietic stem cells and mice display a broad and reproducible pattern of mature human immune cells at 10 to 14 weeks after injection. HuMurine has worked closely with both academic and commercial clients to develop and standardize a reproducible and robust preclinical humanized mouse model. HuMurine Technologies' work culminated in the launch of the Hu-MTM CIEA NOG mousemodel. Based on this novel platform, HuMurine has recently announced the launch of four new preclinical models to cater to the specific needs of clients seeking to perform studies relating to cancer, infectious disease and immunotherapy.